Organization
Boehringer Ingelheim Pharma GmbH & Co. KG
7 abstracts
Abstract
Phase I, open-label, dose-escalation trial investigating the safety and efficacy of oncolytic virus BI 1821736 in patients with advanced solid tumors.Org: Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Limited,
Abstract
Phase Ia/Ib trial of zongertinib (BI 1810631), a HER2-specific tyrosine kinase inhibitor (TKI), in patients (pts) with HER2 aberration-positive solid tumors: Updated Phase Ia data from Beamion LUNG-1, including progression-free survival (PFS) data.Org: Mary Crowley Cancer Research Center, Guangdong Lung Cancer Institute, Valkyrie Clinical Trials, Inc, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals, Inc.,
Abstract
Treatment of patients with dedifferentiated liposarcoma (DDLPS) with the MDM2–p53 antagonist brigimadlin and p53 function: A longitudinal analysis of circulating microRNAs (miRNAs) in a first-in-human phase Ia/Ib study.Org: Boehringer Ingelheim Pharma GmbH & Co. KG, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, National Cancer Center Hospital East, Kashiwa, Japan, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Maria Skłodowska-Curie National Research Institute of Oncology, Kraków, Poland,
Abstract
Longitudinal mutational analysis of TP53 in plasma circulating tumor DNA (ctDNA) in patients (pts) with solid tumors in a phase I study of BI 907828, an MDM2–p53 antagonist.Org: Boehringer Ingelheim Pharma GmbH & Co. KG, Memorial Sloan Kettering Cancer Center, National Cancer Center Hospital East, Kashiwa, Japan, Sarah Cannon Research Institute/Tennessee Oncology, Florida Cancer Specialists & Research Institute,
Abstract
Phase I Beamion Lung 1 trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations: Updated data.Org: MD Anderson Cancer Center, Department of Clinical Pharmacology, The Netherlands Cancer Institute, Mary Crowley Cancer Research Center, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,
Abstract
A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients (pts) with solid tumors: Safety and efficacy in patients with dedifferentiated liposarcoma (DDLPS).Org: Yale University School of Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, CT, Memorial Sloan Kettering Cancer Center, Department of Experimental Therapeutics, National Cancer Center Hospital East, Sarah Cannon Research Institute/Tennessee Oncology,
Abstract
“EFFECTIVE LUNG AGE” IN SUBJECTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSc-ILD) IN THE SENSCIS TRIALOrg: Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, University of Montpellier, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), University Hospital Zurich,